Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesGenetic & Molecular TestingCBHA Dermatologic Genetic Testing Coverage | OpenP…
    Ask Trek AI about this page
    ModifiedCarolina Behavioral Health Alliance (CBHA)Policy N/A

    Concert Genetic Testing: Dermatologic Conditions

    Customize your policy alerts

    Sign up for all carolinabehavioralhealth policy alerts

    Know when carolinabehavioralhealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy establishes medical-necessity criteria for genetic testing used to establish or confirm capillary malformation-arteriovenous malformation syndrome, congenital ichthyosis, and other genetically associated dermatologic conditions.

    Policy Summary
    PayerCarolina Behavioral Health Alliance (CBHA)
    PolicyConcert Genetic Testing: Dermatologic Conditions
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the member’s qualifying clinical findings when requesting genetic testing for dermatologic conditions.
    SourceLink
    POLICY UPDATE CHANGES

    Criteria for known familial variant analysis in dermatologic conditions were moved to the General Approach to Genetic and Molecular Testing policy.

    A prior criteria set for Epidermolysis Bullosa multigene panels based on low order and claim volume was retired.

    The minimum gene-list requirement for Congenital Ichthyosis multigene panels was removed.

    The policy title, coding, reference table, background, references, and terminology were updated through the November 2024 revision.

    Criteria for known familial variant analysis in dermatologic conditions were moved to the separate policy Genetic Testing: General Approach to Genetic and Molecular Testing.

    The criteria set for Epidermolysis Bullosa multigene panels was retired.

    The minimum gene-list requirement for Congenital Ichthyosis multigene panels was removed.

    The policy title and background terminology were updated to align with the RASA1 and EPHB4 sequencing, deletion/duplication analysis, or multigene panel criteria.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3Primary coverage sections
    3CM-AVM qualifying findings
    5Listed dermatologic conditions
    2Coded test categories
    V1.2025Policy version
    3Named criteria changes

    Medical Necessity Criteria

    CM-AVM syndrome testing

    Covered when the member/enrollee displays one or more qualifying clinical findings.

    Qualifying CM-AVM clinical finding

    • Capillary malformations
    • Arteriovenous abnormality: Arteriovenous malformations or arteriovenous fistulas
    • Parkes Weber syndrome phenotype, consisting of a cutaneous capillary malformation associated with underlying multiple micro-arteriovenous fistulas and soft-tissue and skeletal hypertrophy of the affected limb

    Congenital ichthyosis multigene panels

    Covered when all of the following are met.

    Congenital ichthyosis testing criteria

    • Scaly skin phenotype: Scaly skin with or without a history of harlequin ichthyosis, collodion membrane, or thick, hyperkeratotic skin
    • Associated clinical finding

      • Ectropion (eversion of eyelids)
      • Eclabium (eversion of lips)
      • Scarring alopecia
      • Palmoplantar hyperkeratosis: Palmar and/or plantar hyperkeratosis
      • Erythroderma (red skin)

    Other covered dermatologic conditions

    Covered when the member/enrollee demonstrates clinical features consistent with the condition and testing is intended to establish or confirm the diagnosis to guide management.

    Covered dermatologic condition

    • Hidrotic ectodermal dysplasia 2: Hidrotic Ectodermal Dysplasia 2 (Clouston Syndrome)
    • Hypohidrotic ectodermal dysplasia: Hypohidrotic Ectodermal Dysplasia
    • X-linked ocular albinism: Ocular albinism, X-linked
    • Oculocutaneous albinism
    • Epidermolysis bullosa:

    CM-AVM testing is investigational for indications other than the specified qualifying findings: capillary malformations, arteriovenous malformations or fistulas, or a Parkes Weber syndrome phenotype.

    Congenital ichthyosis multigene panel testing is investigational for all other indications, including cases without scaly skin and at least one specified associated clinical finding.

    Covered Testing Indications

    Establishing CM-AVM syndrome

    Covered to establish a diagnosis of capillary malformation-arteriovenous malformation (CM-AVM) syndrome when the member/enrollee has at least one qualifying clinical finding and testing is performed using an allowed method.

    CM-AVM diagnosis

    • Qualifying clinical finding

      • Capillary malformations
      • Arteriovenous malformations or arteriovenous fistulas
      • Parkes Weber syndrome phenotype: a cutaneous capillary malformation associated with underlying multiple micro-arteriovenous fistulas and soft-tissue and skeletal hypertrophy of the affected limb
    • Permitted testing method

    Coding and Applicable Diagnoses

    CM-AVM testingCPTCovered
    81479RASA1 and EPHB4 sequencing and/or deletion/duplication analysis or multigene panel analysis
    Congenital Ichthyosis Multigene PanelsCPTCovered
    81405Congenital ichthyosis multigene panels
    81479Congenital ichthyosis multigene panels
    CM-AVM common ICD codesICD-10
    Q27.3Arteriovenous malformation of peripheral vessels
    Q27.9Congenital malformation of peripheral vascular system, unspecified
    Congenital Ichthyosis common ICD codeICD-10
    Q80Ichthyosis

    Documentation and Denial Considerations

    Documentation Required

    CM-AVM Clinical Findings Required

    Document one or more qualifying clinical findings supporting CM-AVM testing before ordering RASA1 and EPHB4 sequencing and/or deletion/duplication analysis or multigene panel analysis (81479).

    • Capillary malformations
    • Arteriovenous malformations or arteriovenous fistulas
    • Parkes Weber syndrome phenotype: a cutaneous capillary malformation associated with underlying multiple micro-AVFs and soft-tissue and skeletal hypertrophy of the affected limb
    Denial Risk

    CM-AVM Testing Without Qualifying Findings

    CM-AVM testing (81479) is considered investigational when the member does not display at least one qualifying clinical finding.

    • Testing is investigational for indications other than documented capillary malformations, arteriovenous malformations/fistulas, or a Parkes Weber syndrome phenotype

    Investigational or Noncovered Indications

    Testing for CM-AVM syndrome is not covered when the member does not have capillary malformations, arteriovenous malformations or fistulas, or a Parkes Weber syndrome phenotype. Congenital ichthyosis multigene panel testing is not covered for indications outside the specified scaly-skin phenotype and associated findings, including ectropion, eclabium, scarring alopecia, palmar or plantar hyperkeratosis, or erythroderma.

    Clinical Background

    Genetic testing for dermatologic conditions can help confirm a diagnosis in a patient with relevant signs or symptoms, guide or alter management, and eliminate the need for additional diagnostic workup. Testing may evaluate disease-associated variants, including variants associated with CM-AVM syndrome and inherited disorders characterized by congenital ichthyosis.

    Condition Definitions

    Parkes Weber syndrome phenotype
    Cutaneous findingA cutaneous capillary malformation
    Vascular findingUnderlying multiple micro-arteriovenous fistulas (micro-AVFs)
    Soft-tissue findingSoft-tissue hypertrophy of the affected limb
    Skeletal findingSkeletal hypertrophy of the affected limb
    Congenital ichthyosis
    DefinitionA group of inherited disorders characterized by scaly skin
    Associated presentationMay occur with a history of harlequin ichthyosis or collodion membrane
    Policy Summary
    PayerCarolina Behavioral Health Alliance (CBHA)
    PolicyConcert Genetic Testing: Dermatologic Conditions
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument the member’s qualifying clinical findings when requesting genetic testing for dermatologic conditions.
    SourceLink
    On This Page
    Medical Necessity CriteriaCovered Testing IndicationsCoding and Applicable DiagnosesDocumentation and Denial ConsiderationsInvestigational or Noncovered IndicationsClinical BackgroundCondition Definitions
    Epidermolysis Bullosa
  1. Other dermatologic condition: Another dermatologic condition evaluated under the General Approach to Genetic and Molecular Testing policy

    The listed conditions are not intended to be comprehensive.

  2. RASA1 and EPHB4 sequencing
  3. RASA1 and EPHB4 deletion/duplication analysis
  4. CM-AVM multigene panel analysis
  5. Establishing or confirming congenital ichthyosis

    Covered to establish or confirm congenital ichthyosis when all of the following are met.

    Congenital ichthyosis diagnosis

    • Scaly skin phenotype: The member/enrollee has scaly skin, with or without a history of harlequin ichthyosis, collodion membrane, or thick, hyperkeratotic skin
    • Qualifying associated clinical finding

      • Ectropion (eversion of eyelids)
      • Eclabium (eversion of lips)
      • Scarring alopecia
      • Palmar and/or plantar hyperkeratosis
      • Erythroderma (red skin)
    • Permitted testing method: Congenital ichthyosis multigene panel analysis is performed

      Applicable CPT codes are 81405 and 81479.

    Other genetically associated dermatologic conditions

    Covered to establish or confirm a genetically associated dermatologic condition to guide management when the member/enrollee demonstrates clinical features consistent with the condition.

    Genetically associated dermatologic condition

    • Condition being evaluated

      • Hidrotic Ectodermal Dysplasia 2 (Clouston Syndrome)
      • Hypohidrotic Ectodermal Dysplasia
      • Ocular albinism, X-linked
      • Oculocutaneous albinism
      • Epidermolysis Bullosa
    • Consistent clinical features: The member/enrollee demonstrates clinical features consistent with the condition
    • Purpose of testing: Testing is intended to establish or confirm the diagnosis to guide management
    Documentation Required

    Congenital Ichthyosis Clinical Findings Required

    Document scaly skin and at least one associated clinical finding to support congenital ichthyosis multigene panel analysis (81405, 81479).

    • Scaly skin, with or without a history of harlequin ichthyosis, collodion membrane, or thick, hyperkeratotic skin
    • At least one of the following: ectropion, eclabium, scarring alopecia, palmar and/or plantar hyperkeratosis, or erythroderma
    Denial Risk

    Ichthyosis Testing Without Qualifying Phenotype

    Congenital ichthyosis multigene panel testing (81405, 81479) is considered investigational when the required scaly-skin phenotype and at least one associated clinical finding are not documented.

    • Testing is investigational when qualifying phenotype and associated findings are absent
    Documentation Required

    Other Dermatologic Condition Documentation

    For other dermatologic conditions with a known genetic association, document clinical features consistent with the condition and that testing is intended to establish or confirm the diagnosis to guide management.

    • Examples include hidrotic ectodermal dysplasia 2 (Clouston syndrome), hypohidrotic ectodermal dysplasia, X-linked ocular albinism, oculocutaneous albinism, and epidermolysis bullosa
    • Other dermatologic conditions not specifically addressed will be evaluated under the General Approach to Genetic and Molecular Testing criteria
    Skin manifestationsThick, hyperkeratotic skin, palmoplantar hyperkeratosis, or erythroderma (red skin)
    Other clinical manifestationsEctropion (eversion of the eyelids), eclabium (eversion of the lips), or scarring alopecia
    Capillary malformation-arteriovenous malformation syndrome
    Clinical definitionA disorder associated with suggestive clinical findings, including capillary malformations, arteriovenous malformations or fistulas, or a Parkes Weber syndrome phenotype
    Molecular definitionEstablished by identification of a heterozygous pathogenic variant in EPHB4 or RASA1 through molecular genetic testing
    Testing approachMolecular genetic testing may include a multigene panel containing EPHB4, RASA1, and other genes of interest